Worldwide HealthcareWWH:LSE

6.00 / 0.45 %
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 28 2014 16:38 BST.

Total returns on £1000

Fund / BenchmarkChange
PriceWorldwide Healthcare (Ordinary Share)+17.69 %
Worldwide Healthcare (Ordinary Share)+20.95 %
Morningstar's BenchmarkFTSE World+7.33 %
As of Jul 28 2014.

Worldwide Healthcare summary

Shares outstanding48.15m
Market cap619.20m GBP
Total assets723.10m GBP
Total expense ratio2.77%
Day high1,334
Day low1,317
Previous close1,326
Average volume50.23k
YTD Change+6.54 %
Diluted NAV (est)1,390.4
Diluted NAV (last pub)1,406.25
Premium/Discount-5.06 %
Gearing+110.00 %
52-week range
Aug 20 2013
Feb 28 2014

As of last trade WWH:LSE traded at 1,320, 6.25 % below its 52-week high of 1,408, set on Feb 28, 2014.

Data delayed at least 15 minutes, as of Jul 28 2014 16:38 BST.


Management group(s)OrbiMed Capital LLC
AIC sectorSector Specialist: Biotechnology/Life Sciences
Launch date28 Apr 1995
Share typeOrdinary Share
Base currencyGBP


To invest worldwide in pharmaceutical and biotechnology companies with the aim of achieving a high level of capital growth.

Management & contract fees

Frostrow Capital LLP receives a periodic fee equal to 0.30% p.a. of the Company's market capitalization up to GBP150m, 0.20% p.a. of the market capitalization in excess of GBP150m and up to GBP500m, and 0.125% p.a. of the market capitalization in excess of GBP500m, plus a fixed amount equal to GBP 57,500 per annum. Performance fee 16.5% of out-performance of NAV over the benchmark, lower of benchmark at quarter end date and at corresponding quarter end in previous year.


Div yield1.25691
Div ex-date04 Jun 2014
Div pay-date04 Jul 2014

Managed by

Samuel. D Isaly Start : 26 Feb 2009
Data delayed at least 15 minutes, as of Jul 28 2014 16:38 BST.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.